Expectativas del paciente y su correlación con la escala de Constant y el cuestionario de calidad de vida SF-36

El objetivo del estudio es la evaluación subjetiva del hombro a través del análisis de expectativas en el dolor, la funcionalidad, las actividades de la vida diaria y la fuerza que el paciente espera obtener tras el tratamiento de la patología del hombro, y posteriormente, evaluar la correlación de estos datos obtenidos con los resultados en la escala de Constant y en el SF- 36. La hipótesis que nos planteamos fue que las expectativas del paciente son independientes del estado funcional del hombro y de la percepción de la calidad de vida.

Artrodesis posterior C1-C2. Resultados y comparación de la fijación transarticular e interarticular en una serie de 36 pacientes

Objetivo. Analizar los resultados de la fijación transarticular e interarticular en dos series de pacientes. Métodos. Se analizaron 36 pacientes con inestabilidad C1-C2, 20 tratados mediante fijación transarticular, y 15 con fijación interarticular. Se obtuvieron datos sobre las complicaciones, evolución radiológica y resultados clínicos. Resultados. De los tratados con fijación transarticular se obtuvieron resultados buenos en 17 casos, regular en 2 y malo en 1. En la fijación interarticular en 14 se obtuvieron un buen resultado, y regular en 2. Conclusiones. La fijación C1-C2 transarticular e interarticular resulta segura, con presentando altas tasas de buenos resultados con pocas complicaciones.

El diari de classe del mestre Ferran Rahola (curs 1935-36)

Ferran Rahola i Auguet va néixer a Girona el 14 de maig de 1914, fill primogènit de l'escriptor Carles Rahola i Llorens i de Rosa Auguet i Farró. Va viure i estudiar a la ciutat durant la seva infantesa i joventut, i després de cursar el batxillerat a l'institut va ingressar a estudiar magisteri a l'Escola Normal de Girona. Va iniciar els seus estudis el curs 1932-33 amb l'anomenat Pla Professional de 1931, el qual ha estat, en opinió deis estudiosos, el millor que han tingut les escoles normals d'Espanya, i responia al projecte global educatiu republicà, un dels pilars bàsics de la formació inicial de mestres. Es tractava d'uns estudis de magisteri professionals, amb un entroncament directe amb les escoles

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study

BACKGROUND: With many atypical antipsychotics now available in the market, it has become a common clinical practice to switch between atypical agents as a means of achieving the best clinical outcomes. This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting. METHODS: W-SOHO was a 3-year observational study that involved over 17,000 outpatients with schizophrenia from 37 countries worldwide. The present post hoc study focused on the subgroup of patients who started taking olanzapine at baseline and subsequently made the first switch to risperidone (n=162) and vice versa (n=136). Clinical status was assessed at the visit when the first switch was made (i.e. before switching) and after switching. Logistic regression models examined the impact of medication switch on tolerability outcomes, and linear regression models assessed the association between medication switch and change in the Clinical Global Impression-Schizophrenia (CGI-SCH) overall score or change in weight. In addition, Kaplan-Meier survival curves and Cox-proportional hazards models were used to analyze the time to medication switch as well as time to relapse (symptom worsening as assessed by the CGI-SCH scale or hospitalization). RESULTS: 48% and 39% of patients switching to olanzapine and risperidone, respectively, remained on the medication without further switches (p=0.019). Patients switching to olanzapine were significantly less likely to experience relapse (hazard ratio: 3.43, 95% CI: 1.43, 8.26), extrapyramidal symptoms (odds ratio [OR]: 4.02, 95% CI: 1.49, 10.89) and amenorrhea/galactorrhea (OR: 8.99, 95% CI: 2.30, 35.13). No significant difference in weight change was, however, found between the two groups. While the CGI-SCH overall score improved in both groups after switching, there was a significantly greater change in those who switched to olanzapine (difference of 0.29 points, p=0.013). CONCLUSION: Our study showed that patients who switched from risperidone to olanzapine were likely to experience a more favorable treatment course than those who switched from olanzapine to risperidone. Given the nature of observational study design and small sample size, additional studies are warranted.